Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Cancer Cell. 2008 Jun;13(6):519-28. doi: 10.1016/j.ccr.2008.04.016.

    The role of SPINK1 in ETS rearrangement-negative prostate cancers.

    Source

    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

    Abstract

    ETS gene fusions have been characterized in a majority of prostate cancers; however, the key molecular alterations in ETS-negative cancers are unclear. Here we used an outlier meta-analysis (meta-COPA) to identify SPINK1 outlier expression exclusively in a subset of ETS rearrangement-negative cancers ( approximately 10% of total cases). We validated the mutual exclusivity of SPINK1 expression and ETS fusion status, demonstrated that SPINK1 outlier expression can be detected noninvasively in urine, and observed that SPINK1 outlier expression is an independent predictor of biochemical recurrence after resection. We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers.

    PMID:
    18538735
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2732022
    Free PMC Article

    Images from this publication.See all images (5)Free text

    Figure 2
    Figure 4
    Figure 1
    Figure 3
    Figure 5

    Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

    Publication Types

    MeSH Terms

    Substances

    Secondary Source ID

    Grant Support

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk